Changing from preserved, to preservative-free cyclosporine 0.1% enhanced triple glaucoma therapy: impact on ocular surface disease—a randomized controlled trial

Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312–34.

Article  CAS  PubMed  Google Scholar 

Banitt M, Jung H. Ocular surface disease in the glaucoma patient. Int Ophthalmol Clin. 2018;58:23–33.

Article  PubMed  Google Scholar 

Wong ABC, Wang MTM, Liu K, Prime ZJ, Danesh-Meyer HV, Craig JP. Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye. Ocul Surf. 2018;16:289–93.

Article  PubMed  Google Scholar 

Clayton JA. Dry eye. N. Engl J Med. 2018;378:2212–23.

Article  CAS  PubMed  Google Scholar 

Pflugfelder SC, Baudouin C. Challenges in the clinical measurement of ocular surface disease in glaucoma patients. Clin Ophthalmol. 2011;5:1575–83.

PubMed  PubMed Central  Google Scholar 

Holló G, Katsanos A, Boboridis KG, Irkec M, Konstas AGP. Preservative-free prostaglandin analogs and prostaglandin/timolol fixed combinations in the treatment of glaucoma: efficacy, safety and potential advantages. Drugs. 2018;78:39–64.

Article  PubMed  Google Scholar 

Zhang X, Vadoothker S, Munir WM, Saeedi O. Ocular surface disease and glaucoma medications: a clinical approach. Eye Contact Lens. 2019;45:11–8.

Article  PubMed  PubMed Central  Google Scholar 

Figus M, Agnifili L, Lanzini M, Brescia L, Sartini F, Mastropasqua L, et al. Topical preservative-free ophthalmic treatments: an unmet clinical need. Expert Opin Drug Deliv. 2021;18:655–72.

Article  PubMed  Google Scholar 

Stalmans I, Lemij H, Clarke J, Baudouin C on behalf of the GOAL study group. Signs and symptoms of ocular surface disease: the reasons for patient dissatisfaction with glaucoma treatments. Clin Ophthalmol. 2020;14:3675–80.

Article  PubMed  PubMed Central  Google Scholar 

Wolfram C, Stahlberg E, Pfeiffer N. Patient-reported nonadherence with glaucoma therapy. J Ocul Pharm Ther. 2019;35:223–8.

Article  CAS  Google Scholar 

Konstas AGP, Labbe A, Katsanos A, Meier-Gibbons F, Irkec M, Boboridis KG, et al. The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability. Expert Opin Drug Saf. 2021;20:453–66.

Article  CAS  PubMed  Google Scholar 

Goldstein MH, Silva FQ, Blender N, Tran T, Vantipalli S. Ocular benzalkonium chloride exposure: problems and solutions. Eye. 2022;36:361–8.

Article  PubMed  Google Scholar 

Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112:1446–54.

Article  CAS  PubMed  Google Scholar 

Boimer C, Birt CM. Preservative exposure and surgical outcomes in glaucoma patients: the PESO study. J Glaucoma. 2013;22:730–5.

Article  PubMed  Google Scholar 

Chamard C, Larrieu S, Baudouin C, Bron A, Villain M, Daien V. Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008-2016. Acta Ophthalmol. 2020;98:e876–881.

Article  PubMed  Google Scholar 

European Glaucoma Society. Terminology and guidelines for glaucoma. 5th ed. Savona, Italy: PubliComm; 2020.

Google Scholar 

Musch DC, Gillespie BW, Niziol LM, Lichter PR, Varma R, CIGTS Study Group. Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2011;118:1766–73.

Article  PubMed  Google Scholar 

Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350–5.

Article  PubMed  Google Scholar 

Portela RC, Fares NT, Machado LF, São Leão AF, de Freitas D, Paranhos A Jr, et al. Evaluation of ocular surface disease in patients with glaucoma: clinical parameters, self-report assessment, and keratograph analysis. J Glaucoma. 2018;27:794–801.

Article  PubMed  Google Scholar 

Boboridis KG, Konstas AGP. Evaluating the novel application of cyclosporine 0.1% in ocular surface disease. Expert Opin Pharmacother. 2018;19:1027–39.

Article  CAS  PubMed  Google Scholar 

Labbe A, Terry O, Brasnu E, Van Went C, Baudouin C. Tear film osmolarity in patients treated for glaucoma or ocular hypertension. Cornea. 2012;31:994e9.

Article  Google Scholar 

Mohammed I, Kulkarni B, Faraj LA, Abbas A, Dua HS, King AJ. Profiling ocular surface responses to preserved and non-preserved topical glaucoma medications: A 2-year randomized evaluation study. Clin Exp Ophthalmol. 2020;48:973–82.

Article  PubMed  Google Scholar 

Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341–9.

Article  CAS  PubMed  Google Scholar 

Steven DW, Alaghband P, Lim KS. Preservatives in glaucoma medication. Br J Ophthalmol. 2018;102:1497–503.

Article  PubMed  Google Scholar 

Saini M, Dhiman R, Dada T, Tandon R, Vanathi M. Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications. Eye. 2015;29:808–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou XQ, Wei RL. Topical cyclosporine A in the treatment of dry eye: a systematic review and meta-analysis. Cornea. 2014;33:760–7.

Article  PubMed  Google Scholar 

Kymionis GD, Bouzoukis DI, Diakonis VF, Siganos C. Treatment of chronic dry eye: focus on cyclosporine. Clin Ophthalmol. 2008;2:829–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee SY, Wong TT, Chua J, Boo C, Soh YF, Tong L. Effect of chronic anti-glaucoma medications and trabeculectomy on tear osmolarity. Eye. 2013;27:1142–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leonardi A, Messmer EM, Labetoulle M, Amrane M, Garrigue JS, Ismail D, et al. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies. Br J Ophthalmol. 2019;103:125–31.

Article  PubMed  Google Scholar 

Konstas AG, Kahook MY, Araie M, Katsanos A, Quaranta L, Rossetti L, et al. Diurnal and 24-h intraocular pressures in glaucoma: monitoring strategies and impact on prognosis and treatment. Adv Ther. 2018;35:1775–804.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Behrens A, Doyle JJ, Stern L, Chuck RS, McDonnell PJ, Azar DT, et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea. 2006;25:900–7.

Article  PubMed  Google Scholar 

Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15:276–83.

Article  PubMed  Google Scholar 

Tomlinson A, Bron AJ, Korb DR, Amano S, Paugh JR, Pearce EI, et al. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Investig Ophthalmol Vis Sci. 2011;52:2006–49.

Article  Google Scholar 

Kim DW, Seo JH, Lim SH. Evaluation of ocular surface disease in elderly patients with glaucoma: expression of matrix metalloproteinase-9 in tears. Eye. 2021;35:892–900.

Article  CAS  PubMed  Google Scholar 

Batra R, Tailor R, Mohamed S. Ocular surface disease exacerbated glaucoma: optimizing the ocular surface improves intraocular pressure control. J Glaucoma. 2014;23:56–60.

Article  PubMed  Google Scholar 

Dubrulle P, Labbé A, Brasnu E, Liang H, Hamard P, Meziani L, et al. Influence of treating ocular surface disease on intraocular pressure in glaucoma patients intolerant to their topical treatments: a report of 10 cases. J Glaucoma. 2018;27:1105–11.

Article  PubMed  Google Scholar 

Baudouin C, Denoyer A, Desbenoit N, Hamm G, Grise A. In vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2012;110:40–63.

PubMed  PubMed Central  Google Scholar 

Baudouin C, Messmer EM, Aragona P, Geerling G, Akova YA, Benítez-del-Castillo J, et al. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol. 2016;100:300–6.

Article  PubMed  Google Scholar 

Periman LM, Mah FS, Karpecki PM. A review of the mechanism of action of cyclosporine A: the role of cyclosporine A in dry eye disease and recent formulation developments. Clin Ophthalmol. 2020;14:4187–200.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schargus M, Ivanova S, Kakkassery V, Dick HB, Joachim S. Correlation of tear film osmolarity and 2 different MMP-9 tests with common dry eye tests in a cohort of non-dry eye patients. Cornea. 2015;34:739–44.

留言 (0)

沒有登入
gif